|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) University of Texas |
|---|---|
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00040053 |
Purpose
The purpose of this study is to assess ondansetron for the treatment of methamphetamine dependence.
| Condition | Intervention | Phase |
|---|---|---|
|
Amphetamine-Related Disorders |
Drug: Ondansetron |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Dose Comparison |
| Official Title: | Double-Blind, Placebo-Controlled, Dose Response Trial of Ondansetron for the Treatment of Methamphetamine Dependence. |
| Estimated Enrollment: | 154 |
| Study Start Date: | June 2002 |
| Study Completion Date: | February 2004 |
This study was designed to be a preliminary assessment of the efficacy and safety of 3-wide range doses of ondansetron (0.25, 1.0 and 4.0 mg taken orally twice per day) to reduce methamphetamine use in subjects with methamphetamine dependence and to determine the optimal dose of ondansetron.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
18 years of age. Treatment seeking for meth dependence.
Exclusion Criteria:
Please contact site director for more details.
Contacts and Locations| United States, California | |
| Matrix Institute on Addictions | |
| Costa Mesa, California, United States, 92627 | |
| South Bay Treatment Center | |
| Chula Vista, California, United States, 91911 | |
| United States, Hawaii | |
| John A. Burns School of Medicine | |
| Honolulu, Hawaii, United States, 96813 | |
| United States, Iowa | |
| Powell Chemical Dependency Center | |
| Des Moines, Iowa, United States, 50316 | |
| United States, Missouri | |
| University of Missouri - Kansas City | |
| Kansas City, Missouri, United States, 64108 | |
| United States, Texas | |
| University of Texas Health Science Center | |
| Houston, Texas, United States, 77225 | |
| Principal Investigator: | Thomas Newton, M.D. | National Institute on Drug Abuse (NIDA) |
More Information
| Study ID Numbers: | NIDA-CTO-0011-1 |
| Study First Received: | June 18, 2002 |
| Last Updated: | July 21, 2008 |
| ClinicalTrials.gov Identifier: | NCT00040053 |
| Health Authority: | United States: Federal Government; United States: Food and Drug Administration |
|
Methamphetamine Dopamine Mental Disorders Amphetamine-Related Disorders Substance-Related Disorders |
Disorders of Environmental Origin Amphetamine Ondansetron Serotonin |
|
Dopamine Uptake Inhibitors Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Adrenergic Agents Molecular Mechanisms of Pharmacological Action Adrenergic Uptake Inhibitors Physiological Effects of Drugs Psychotropic Drugs Antiemetics Serotonin Antagonists Therapeutic Uses Antipruritics Dermatologic Agents |
Tranquilizing Agents Sympathomimetics Gastrointestinal Agents Central Nervous System Depressants Central Nervous System Stimulants Antipsychotic Agents Pharmacologic Actions Serotonin Agents Autonomic Agents Anti-Anxiety Agents Dopamine Agents Peripheral Nervous System Agents Central Nervous System Agents |
